Latest C-peptide Stories
ORLANDO, Fla., June 28 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today presented an analysis of baseline data from the Phase 3 DEFEND-1 clinical trial of otelixizumab in patients with autoimmune new onset type 1 diabetes.
CRANBURY, N.J., June 21 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results of preclinical studies in respiratory tissue with PL-3994.
JERUSALEM, May 26, 2010 /PRNewswire-FirstCall/ -- - Study Data Shows ORMD-0801 Resulted in Glucose and C-Peptide Reduction Oramed Pharmaceuticals Inc.
CRANBURY, N.J., May 11 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its third quarter, fiscal year 2010 financial results on Thursday, May 13, 2010 before the open of the U.S.
JERUSALEM, Israel, May 6, 2010 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc.
CRANBURY, N.J., May 4 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,709,484, titled "Substituted Melanocortin Receptor-Specific Piperazine Compounds," today.
ST. LOUIS, Feb. 25 /PRNewswire/ -- Supelco, a division of Sigma-AldrichÂ® (Nasdaq: SIAL), announced today the launch of Ascentis Express Peptide ES-C18, a high-speed, high-performance liquid chromatography (HPLC) column based on a new 160 angstrom Fused-Core(TM) particle design.
SALEM, N.H., Jan. 26 /PRNewswire/ -- ALPCO Diagnostics has developed two new low-sample volume ELISAs for the quantitative analysis of total proinsulin (I and II) in rats and mice.
CAMBRIDGE, Mass., Jan. 7 /PRNewswire/ -- Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND-1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune type 1 diabetes.
CRANBURY, N.J., Dec. 1 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.